Alterity Therapeutics Limited – Sponsored ADR (ATHE) – What Are Investment Firms Thinking About This Stock?

Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) have been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $10.00.

Several equities analysts recently weighed in on the stock. JonesTrading started coverage on shares of Alterity Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $16.00 price target on the stock. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. Lake Street Capital assumed coverage on shares of Alterity Therapeutics in a research note on Tuesday, September 15th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings raised shares of Alterity Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 12th. Finally, Craig Hallum set a $2.00 price objective on shares of Alterity Therapeutics in a report on Tuesday, August 11th.

Alterity Therapeutics Trading Down 2.8%

Alterity Therapeutics stock opened at $2.09 on Friday. The business’s 50-day simple moving average is $3.74 and its two-hundred day simple moving average is $4.27. Alterity Therapeutics has a fifty-two week low of $2.04 and a fifty-two week high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter. As a group, analysts expect that Alterity Therapeutics will post -0.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alterity Therapeutics stock. Greenleaf Trust raised its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 62,000 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Greenleaf Trust owned 0.70% of Alterity Therapeutics worth $333,000 at the end of the most recent reporting period. 2.14% of the stock is owned by hedge funds and other institutional investors.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on protein misfolding and aggregation, biological processes associated with conditions such as multiple system atrophy (MSA) and Parkinson’s disease.

Alterity’s lead drug candidate is ATH434, an orally administered small molecule designed to inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative disorders.